Mutations of the retinoblastoma tumor suppressor gene RB are frequently observed in human cancers, but rarely in non-small cell lung carcinomas (NSCLCs). Emerging evidence also suggests that the RB-related gene p130 is inactivated in a subset of human NSCLCs. To directly test the specific tumor suppressor roles of RB and p130 in NSCLC, we crossed Rb and p130 conditional mutant mice to mice carrying a conditional oncogenic K-Ras allele. In this model, controlled oncogenic K-Ras activation leads to the development of adenocarcinoma, a major subtype of NSCLC. We found that loss of p130 accelerated the death of mice, providing direct evidence in vivo that p130 is a tumor suppressor gene, albeit a weak one in this context. Loss of Rb increased the efficiency of lung cancer initiation and resulted in the development of high-grade adenocarcinomas and rapid death. Thus, despite the low frequency of RB mutations in human NSCLCs and reports that K-Ras activation and loss of RB function are rarely found in the same human tumors, loss of Rb clearly cooperates with activation of oncogenic K-Ras in lung adenocarcinoma development in mice.
Deletion of Rb and p130 in lung epithelial cells expressing oncogenic K-Ras
Lung cancer is the leading cause of cancer deaths worldwide. Among lung tumors, lung adenocarcinoma is the most frequent histological subtype (Travis et al., 1995; Greenlee et al., 2001) , and activating mutations in K-Ras are seen in B30% of these tumors (Rodenhuis and Slebos, 1990) . Based on these observations, a mouse model of lung adenocarcinoma has been generated in which nasal instillation of Ad-Cre to the lungs of K-Ras þ /LSLÀG12D conditional mutant mice ( Figure 1a ) results in the expression of oncogenic K-Ras G12D and the development of lesions that resemble human tumors (Jackson et al., 2001) .
The RB tumor suppressor is inactivated in a broad range of human tumors (Classon and Harlow, 2002; Sherr and McCormick, 2002) , including pediatric retinoblastomas and B90% of human small cell lung carcinomas (SCLCs). When RB is not itself mutated, other alterations in components of the RB pathway are found in human tumors (Sherr and McCormick, 2002; Grasemann et al., 2005; Olsson et al., 2006) . For instance, RB is rarely found mutated in lung adenocarcinomas whereas p16
INK4a
, an upstream activator of the pRb protein and the two related proteins p107 and p130, is frequently inactivated in this tumor type (Wistuba et al., 2001) . Recent observations further suggest that increased Ras activity and loss of pRb are incompatible during cell cycle progression and tumorigenesis whereas oncogenic Ras cooperates with loss of p16
INK4a (Kaye, 2002; DeGregori, 2006; Williams et al., 2006) . This may explain the specific genetic alterations in the RB pathway observed in lung adenocarcinoma where constitutive activation of K-Ras is thought to be an initiating event. But loss of pRb function has also been reported to increase Ras activity (Lee et al., 1999) . In addition, loss of Ras activity in Rb mutant cells can promote either cellular differentiation or metastasis, depending on the cellular context (Takahashi et al., 2003 (Takahashi et al., , 2004 Takahashi and Ewen, 2006) , suggesting complex functional interactions between the Ras and pRb pathways during embryonic development and tumorigenesis. However, a direct genetic test of Ras activation and Rb deletion in lung cells in vivo is still lacking. In addition, loss of function of the pRb family member p130 may be part of tumor progression in several types of human cancers, including lung adenocarcinomas (Claudio et al., 2000; Cinti et al., 2005) , but a causal role for loss of p130 in lung cancer progression also remains to be determined.
To determine if pRb and p130 act as suppressors of lung adenocarcinoma development, we crossed K-Ras
mice to mice carrying conditional mutant alleles of Rb (Rb ;Rb 2lox;2lox (Ras/Rb) mice infected with Ad-GFP never developed lung lesions in the 4-6 months time frame of this initial analysis (data not shown), confirming that neither loss of pRb nor p130 function is sufficient for the development of lung cancer (Cobrinik et al., 1996; Meuwissen et al., 2003) , and that the development of lung tumors in this context strictly depends on K-Ras G12D activation. (Tuveson et al., 2004) , Rb (Sage et al., 2000) and p130. p130 conditional mutant mice, in which p130 exon 2 is flanked by lox sites (striped triangles), will be described elsewhere. Mice are maintained according to practices prescribed by the NIH at Stanford's Research Animal Facility accredited by the AAALAC. (b) Presence of deleted Rb and p130 alleles in Ras/Rb and Ras/p130 mutant mice respectively (nX6 for each genotype, one representative example is shown). Tumors were induced in 6-week-old mice by nasal instillation of Ad-Cre and dissected from the lungs of sick animals (Jackson et al., 2001) . Adenoviral stocks were purchased from the Gene Transfer Vector Core facility at the University of Iowa College of Medicine and from the Vector Development Laboratory of Baylor College of Medicine. Genomic DNA from these tumors (Tu) was used as a template for genotyping PCRs. Primer information will be provided upon request. As the dissected tumors often contain inflammatory and stromal cells that have not received Ad-Cre, the non-deleted, conditional LSL-G12D K-Ras allele can often be detected by PCR in these tumors. Tail DNA was used as a control (C). Water was used as a negative control (À) and genomic DNAs from mouse embryonic fibroblasts isolated from mutant mice served as positive controls ( þ ). (c) (Top panel) Western blot analysis of pRb, p130 and p107 levels in lung tumors from Ras, Ras/p130 and Ras/ Rb mutant mice (nX5 for each genotype, three representative examples are shown). Protein extracts from 293 cells were used as positive controls and analysis of GAPDH levels served as a loading control. Extracts from Rb family knockout cells served as negative controls (data not shown); *non-specific signal. Antibodies used were mouse monoclonal antibodies against pRb generated in our laboratory against the C-terminal part of the mouse protein, rabbit polyclonal antibodies against p107 (Santa-Cruz C-18, Santa Cruz, CA, USA), and mouse monoclonal antibodies against p130 (BD 610621) (Sage et al., 2000) . (Middle-Bottom panels) Western blot analysis of cell cycle regulators (nX8 for each genotype, four representative examples are shown): Cyclin E1 (Upstate Biotechnology 07-687, Billerica, MA, USA), Cyclin D1 (Santa-Cruz H-295), Cdk2 (Santa-Cruz M-2), E2F-1 (Santa-Cruz C-20), p21 (Santa-Cruz C-19), Cyclin A1 (Santa-Cruz H-432). Karyopherin (Karyo., Santa-Cruz C-20) and eIF4E (Cell Signaling Technology 9742, Danvers, MA, USA) served as loading controls.
Dissection of Ras, Ras/p130 and Ras/Rb mutant mice infected with Ad-Cre revealed visible tumors growing at the periphery of the lungs. PCR analysis of genomic DNA indicated deletion of the p130 and Rb conditional alleles in tumors arising in Ras/p130 and Ras/Rb mutant mice, respectively, in all cases examined (Figure 1b) . pRb levels were undetectable in all lung tumors by immunoblot but Ras/Rb mutant tumors expressed higher levels of p130 and p107 compared to Ras tumors, indicating that compensatory mechanisms within the Rb gene family occur in the absence of Rb function in lung cells, as observed in other systems (Mulligan et al., 1998; Classon et al., 2000; Sage et al., 2003) . p130 levels are generally low in cycling cells (Tedesco et al., 2002) and were low in Ras mutant tumors, but a compensatory increase in p107 levels again confirmed the loss of p130 in Ras/p130 mutant tumors ( Figure 1c ). Cyclin E1, a key cell cycle regulator whose expression is normally repressed by pRb family proteins (Geng et al., 1996) , was also upregulated in Ras/Rb mutant tumors, whereas Cyclin D1 levels were similar in tumors from the three genotypes. In contrast, E2F-1, itself a target of the pRb/ E2F pathway (Johnson et al., 1994) , showed decreased levels in Ras/p130 and Ras/Rb tumors compared to Ras tumors ( Figure 1c ). Western blot analysis of phosphoepitopes showed that the p42/p44 MAPK, p38 MAPK and AKT signaling pathways were slightly inhibited by loss of pRb or p130 (Supplementary Figure S1) , indicating that loss of these two cell cycle regulators also affects Ras signaling.
These data show that loss of Rb and loss of p130 are compatible with lung cancer development induced by oncogenic K-Ras. In addition, loss of Rb and p130 in K-Ras G12D -induced lung tumors results in complex changes in the levels of cell cycle regulators and in the activity of effectors of Ras signaling, suggesting the existence of intricate feedback loops between the pRb and Ras pathways.
Loss of p130 or Rb does not change the lung tumor type but Rb loss results in higher tumor grade
Loss of p130 in Rb-deficient cells promotes the development of neuroendocrine lesions in the lung of mice (Dannenberg et al., 2004) , and loss of Rb alone leads to an expansion of neuroendocrine cells (WikenheiserBrokamp, 2004) . Thus, the tumor spectrum of Ras/Rb and Ras/p130 double mutant mice may be different from that of Ras mutant mice. However, analysis of lung tumors showed no obvious histopathological differences between tumors from Ras, Ras/p130 and Ras/Rb mutant mice, which all developed lung adenocarcinomas, papillary adenomas and bronchiolar hyperplasia and dysplasia ( Figure 2a ) (Jackson et al., 2001) . Thus, K-Ras signaling is dominant over the pro-neuroendocrine effects of loss of Rb family function.
Based on a previously described grading system (Jackson et al., 2005) , we then sought to compare the tumors present in mice at the time of death in animals of the three genotypes, focusing on the more advanced stages. We found that Ras/Rb mice developed grade 5 (G5) tumors, defined by stromal desmoplasia (myofibroblasts and inflammatory cells set in fibrotic stroma) and are mostly like human adenocarcinomas (Figure 2b ). Tumors from Ras or Ras/p130 mutant animals only developed mild thickening of alveolar septa and fibrovascular cores or rare focal fibrosis within tumors (Figure 2b) , whereas several Ras/Rb mutant mice developed tumors with extensive areas of desmoplasia, sometimes composing the majority of the tumor (data not shown). The numbers of mice in each genotype category that contained definitive G5 tumors were 0% for Ras mutant tumors (nine mice analysed) and Ras/p130 mutant tumors (nine mice analysed), and 25% for Ras/Rb mutant tumors (twelve mice analysed). No lymph node metastases were identified in mice of any genotype (data not shown).
In conclusion, loss of pRb or p130 does not visibly influence the differentiation phenotype of mouse lung tumors induced by K-Ras
G12D
, but loss of Rb results in the development of the highest grade adenocarcinomas.
Increased tumor burden in Ras/Rb mutant mice pRb and p130 are inhibitors of cell cycle progression and tumorigenesis (Dannenberg and te Riele, 2006; Wikenheiser-Brokamp, 2006) , which led us to measure the number and the size of lesions present in the lungs of Ras, Ras/p130 and Ras/Rb mutant mice. 12 weeks after infection with Ad-Cre, when adenomas are well separated (Jackson et al., 2001 (Jackson et al., , 2005 , we found no significant differences in the number of lung lesions and the surface area they occupy when we compared Ras and Ras/p130 mutant mice (Figures 3a and b) . This result suggests that p130 does not normally restrict the initiation of lung cancer by oncogenic K-Ras and does not significantly inhibit the formation of lung adenomas. In contrast, Ras/Rb tumors were significantly more numerous ( Figure 3a) and a trend was observed that they occupied a larger lung volume compared to Ras/ p130 and Ras mutant mice (Figure 3b ), indicating that pRb normally suppresses the initial stages of lung cancer in this mouse model. 22-28 weeks after Ad-Cre infection, total tumor area and the number of lesions were not significantly different between the three genotypes, suggesting that the tumor burden reaches a limit around the time of death (Supplementary Figure S2) . However, the size of Ras/p130 tumors was significantly larger than the size of both Ras and Ras/Rb mutant tumors at that time (Figures 3c). These experiments suggest that p130 may play a more critical tumor suppressor role in the late stages of tumor development, with loss of p130 allowing tumors to reach a larger size.
Tumor size and number depend on multiple parameters, including proliferation and death rates. Independent of the stage and the genotype, lung tumors induced by K-Ras G12D displayed very low levels of apoptotic cell death, as assayed by immunostaining for the cleaved form of caspase 3 (CC3) (Figure 3d and data not shown). These observations suggest that cell death is not a key aspect of lung adenocarcinoma development in these mutant mice, although it is possible that infiltrating macrophages rapidly eliminate dying tumor cells, thereby masking the true rates of cell death. Strikingly, the proliferative indices of tumors of similar sizes, as measured by phospho-histone H3 (PH3) immunostaining on sections of mutant mice 12 , and Ras/Rb mutant mice develop adenomas and adenocarcinomas (white A) and bronchiolar hyperplasia (white B), as visualized in hematoxylin and eosin (H&E) -stained paraffin sections (top panels)-magnification Â 100. For immunostaining, antigens were retrieved using the Trilogy unmasking solution (Cell Marque). The tumors were largely negative for CCSP, a marker of Clara cells, but bronchiolar hyperplasias were positive for CCSP (green, Â 400 -Santa-Cruz S-20). Tumors were positive for SP-C, a marker of alveolar cells (red, Â 400-rabbit antibody from Dr Whitsett), and negative for the neuroendocrine marker Synaptophysin (red over blue DAPI signal, Â 200-Neomarkers Ab-4). Synaptophysin-positive cells (arrowhead) were found in the bronchiolar epithelium, sometimes mixed with hyperplastic cells in the Ras/p130, and Ras/Rb mutant mice (white arrowheads, bottom panels). Although we did observe that clusters of neuroendocrine cells (positive for synaptophysin) had a tendency to be larger in double mutant mice, these neuroendocrine cells were absent from more than 50 tumors analysed between 20 and 30 weeks of age and represented only a very minor fraction of lung cells in the mutant animals (data not shown). (b) Ras/Rb mutant mice develop grade 5 adenocarcinomas with stromal desmoplasia. Representative (H&E) stained paraffin sections of tumors from mice of the listed genotypes at Â 100 (top panels) and Â 400 (bottom panels, from insets) are shown. Whereas tumors from Ras or Ras/p130 mutant mice showed a mild thickening of alveolar septa (asterisk) or small, rare foci of stromal fibrosis (outlined by dotted line, asterisk), several Ras/Rb mutant mice developed tumors with large, prominent areas of stromal desmoplasia (upper panel, outlined by dotted line), composed of myofibroblasts and inflammatory cells in fibrotic, collagenous stroma (double asterisk). The color reproduction of this figure is available on the html full text version of the manuscript.
weeks after Ad-Cre infection were significantly higher in Ras than in Ras/p130 and Ras/Rb mutant mice (Figure 3e ). Ki67 immunostaining on sections of mutant mice 20-25 weeks post-Ad-Cre infection confirmed this observation (Figure 3f ), although the rates of proliferation in Ras/Rb tumors were not as low as those in Ras/ p130 tumors at this later time point.
One interpretation of these observations, supported by previous data (Williams et al., 2006) and our western blot analysis (Figure 1c) , is that compensatory increases in p107 levels block the proliferation of the Ras/p130 mutant lung cells. A similar inhibition of proliferation is initially found in Ras/Rb mutant tumors, although increased levels of p107 and p130 may not be able to compensate as efficiently for loss of pRb as p107 does for loss of p130. In addition, Rb deficiency results in an increased efficiency of tumor initiation, thereby potentially compensating for the decreased proliferative status of the Ras/Rb mutant lesions. At later time points, as cells within tumors accumulate other alterations, loss of p130 results in an increase in tumor size, although the mechanisms underlying this phenotype remain unclear. 
Loss of Rb or p130 accelerates the death from lung cancer of Ras mutant mice
A more direct functional consequence of cooperation between cancer genes can be assessed by studying the mortality of compound mutant mice. Cohorts of Ras, Ras/p130 and Ras/Rb mice were infected with 4 Â 10 7 PFU of Ad-Cre and their survival was monitored (Figure 4) . Here, 17/20 analysed Ras/p130 mice infected with Ad-Cre developed lung tumors. The median lifespan of these Ras/p130 mice was 25 weeks. Similarly, 12/12 analysed Ras/Rb mice had lung tumors at death; their median lifespan was 20 weeks. The median lifespan of nine control Ras mutant mice was 32 weeks. Thus, loss of both p130 and Rb accelerates lung tumor progression in this context.
In mice, loss of p130 function has only been shown to accelerate tumorigenesis in the context of loss of Rb function (Dannenberg and te Riele, 2006; WikenheiserBrokamp, 2006) . Given the extensive functional redundancy between pRb family proteins, it is difficult to conclude from these previous observations if p130 can truly act as a tumor suppressor gene in cells with functional pRb and p107. Although p130 inactivation was found in lymphomas from a retroviral screen in Blm-deficient mice (Suzuki et al., 2006) , our data provide the first direct genetic evidence that p130 plays a tumor suppressor role in vivo in the presence of pRb and p107 and suggest that loss of p130 may accelerate disease progression at the later stages of the tumorigenic process. This observation may explain why mutations in p130 are only observed in a relatively small subset of lung cancers. Thus, increasing evidence supports the idea that p130 is a weak but a bona fide tumor suppressor gene.
Our data also indicate that pRb can efficiently suppress lung cancer development initiated by K-Ras G12D . Lower proliferation rates are observed in Ras/Rb lung tumors, but more lesions are initiated in the double mutant mice that develop into higher-grade adenocarcinomas, eventually leading to the more rapid death of the Ras/Rb double mutant animals. Higher p107 and p130 levels, and lower levels of E2F-1 in Ras/Rb lung tumors may slow down the initial stages of tumorigenesis, but do not prevent cancer progression. Similarly, the induction of skin lesions by Ras activation can occur in a Rb-deficient background, suggesting that p107 cannot block tumorigenesis in Ras/Rb mutant skin cells although loss of p107 in this context further accelerates tumor development (Ruiz et al., 2005; Lara et al., 2008) . Thus, depending on the cellular context, the tumor microenvironment, and potentially other genetic lesions, activation of Ras and loss of pRb function may or may not be compatible with tumorigenesis, and we still cannot explain the counter-selection for RB inactivation over p16
INK4a inactivation in human lung adenocarcinomas.
Interestingly, Ras/p130 and Ras/Rb mutant mice die faster than Ras mutant mice despite slightly lower rates of proliferation, suggesting that the main tumor suppression function of p130 and Rb in this context is not to control cell cycle progression and raising the question of what other cellular function(s) of these tumor suppressors is at play in lung cancer.
In conclusion, we provide in vivo genetic evidence that Rb and p130 have the capacity to act as tumor suppressors of lung adenocarcinoma development, confirming the broad tumor suppressor potential of Rb family genes and raising the possibility that re-activation or induction of pRb family function in lung cancers may be used to slow tumor growth in patients. and two p130 2lox;2lox ;K-ras þ /LSLÀG12D mice were still alive after 75 weeks and were euthanised at that point. These five mice showed no or very few lung tumors, suggesting that the Ad-Cre infection had been ineffective in these animals; these mice were removed from the survival curves.
